MX2017016013A - Compuesto derivativo triciclico, metodo para prepararlo y composicion farmaceutica que comprende el mismo. - Google Patents

Compuesto derivativo triciclico, metodo para prepararlo y composicion farmaceutica que comprende el mismo.

Info

Publication number
MX2017016013A
MX2017016013A MX2017016013A MX2017016013A MX2017016013A MX 2017016013 A MX2017016013 A MX 2017016013A MX 2017016013 A MX2017016013 A MX 2017016013A MX 2017016013 A MX2017016013 A MX 2017016013A MX 2017016013 A MX2017016013 A MX 2017016013A
Authority
MX
Mexico
Prior art keywords
derivative compound
same
tricyclic derivative
tankyrase
pharmaceutical composition
Prior art date
Application number
MX2017016013A
Other languages
English (en)
Inventor
Lee Hyunho
Chun Kwangwoo
Young Joe Bo-
Seon Kim Eun
Sung JANG Eun
OH Hyeongchan
Min Kim Jeong-
PARK Jiseon
Lee Hanchang
Original Assignee
Je Il Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Je Il Pharmaceutical Co Ltd filed Critical Je Il Pharmaceutical Co Ltd
Publication of MX2017016013A publication Critical patent/MX2017016013A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

La presente invención se refiere a nuevos compuestos derivativos tricíclicos y, más concretamente, a compuestos derivativos tricíclicos, isómeros ópticos de los mismos, racematos de los mismos o sales farmacéuticamente aceptables de los mismos que tienen excelente actividad contra PARP-1, tanquirasa-1 o tanquirasa-2. Los compuestos derivativos tricíclicos, los isómeros ópticos de los mismos, los racematos de los mismos o las sales farmacéuticamente aceptables de los mismos de acuerdo con la presente invención tienen actividad inhibidora contra PARP-1, tanquirasa-1 o tanquirasa-2 y, por tanto, se pueden usar eficazmente para la prevención o el tratamiento del dolor neuropático, de enfermedades neurodegenerativas, enfermedades cardiovasculares, neuropatía diabética, enfermedades inflamatorias, osteoporosis o cáncer.
MX2017016013A 2015-06-09 2016-06-03 Compuesto derivativo triciclico, metodo para prepararlo y composicion farmaceutica que comprende el mismo. MX2017016013A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20150081021 2015-06-09
PCT/KR2016/005911 WO2016200101A2 (ko) 2015-06-09 2016-06-03 트리사이클릭 유도체 화합물, 이의 제조방법 및 이를 포함하는 약학적 조성물

Publications (1)

Publication Number Publication Date
MX2017016013A true MX2017016013A (es) 2018-04-20

Family

ID=57503424

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017016013A MX2017016013A (es) 2015-06-09 2016-06-03 Compuesto derivativo triciclico, metodo para prepararlo y composicion farmaceutica que comprende el mismo.

Country Status (21)

Country Link
US (1) US10464919B2 (es)
EP (1) EP3312177B1 (es)
JP (2) JP2018521033A (es)
KR (1) KR101837047B1 (es)
CN (1) CN107849040B (es)
AU (1) AU2016276806B9 (es)
BR (1) BR112017026392B1 (es)
CA (1) CA2990277C (es)
CL (1) CL2017003138A1 (es)
DK (1) DK3312177T3 (es)
ES (1) ES2870203T3 (es)
MX (1) MX2017016013A (es)
MY (1) MY194590A (es)
NZ (1) NZ738187A (es)
PH (1) PH12017502228A1 (es)
PL (1) PL3312177T3 (es)
PT (1) PT3312177T (es)
RU (1) RU2715413C2 (es)
SA (1) SA517390509B1 (es)
WO (1) WO2016200101A2 (es)
ZA (1) ZA201708663B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107949562B (zh) 2015-06-09 2021-07-23 拜耳制药股份公司 毒蕈碱性m2受体的正性变构调节剂
NZ738187A (en) * 2015-06-09 2019-03-29 Je Il Pharmaceutical Co Ltd Tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same
KR101775356B1 (ko) 2015-07-06 2017-09-06 재단법인 아산사회복지재단 Parp 및 탄키라제 동시 저해제에 대한 감수성 결정 방법
CA3030204A1 (en) 2016-07-11 2018-01-18 Bayer Pharma Aktiengesellschaft 7-substituted 1-pyridyl-naphthyridine-3-carboxylic acid amides and use thereof
JOP20190045A1 (ar) 2016-09-14 2019-03-14 Bayer Ag مركبات أميد حمض 1- أريل-نفثيريدين-3-كربوكسيليك مستبدلة في الموضع 7 واستخدامها.
CN108727377A (zh) * 2017-04-14 2018-11-02 四川大学 3-氰基吡唑并[1,5-a]嘧啶衍生物及其制备方法和用途
WO2019134985A1 (en) 2018-01-08 2019-07-11 F. Hoffmann-La Roche Ag Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors
US20220110936A1 (en) * 2019-02-02 2022-04-14 Shanghai Institute Of Organic Chemistry, Chinese Academy Of Sciences Pharmaceutical composition for treatment of neurodegenerative diseases or diseases caused by abnormality of rna binding protein and applications thereof
JP2022527590A (ja) * 2019-04-09 2022-06-02 エフ．ホフマン－ラ ロシュ アーゲー モノアシルグリセロールリパーゼ（ｍａｇｌ）の阻害剤としての複素環式化合物
AU2020318599B2 (en) * 2019-07-19 2023-09-07 Astrazeneca Ab PARP1 inhibitors
JP2022551373A (ja) * 2019-07-29 2022-12-09 ジェイル ファーマシューティカル カンパニー リミテッド 三環式誘導体を用いた脳卒中の治療方法
JP2022544776A (ja) * 2019-08-14 2022-10-21 メトロ インターナショナル バイオテック，エルエルシー ニコチンアミドアデニンジヌクレオチドの差次的モジュレーションのための化合物及び組成物
US11795158B2 (en) * 2020-06-25 2023-10-24 Astrazeneca Ab Chemical compounds
GB202012969D0 (en) * 2020-08-19 2020-09-30 Univ Of Oxford Inhibitor compounds
WO2022225934A1 (en) * 2021-04-19 2022-10-27 Xinthera, Inc. Parp1 inhibitors and uses thereof
BR112023021383A2 (pt) * 2021-04-22 2023-12-19 Wigen Biomedicine Tech Shanghai Co Ltd Composto da fórmula geral 1, ou um isômero, uma forma cristalina, um sal farmaceuticamente aceitável, um hidrato ou um solvato do mesmo; composto de fórmula geral 2, ou um isômero, uma forma cristalina, um sal farmaceuticamente aceitável, um hidrato ou um solvato do mesmo; composto de fórmula geral 3, ou um isômero, uma forma cristalina, um sal farmaceuticamente aceitável, um hidrato ou um solvato do mesmo; composto de fórmula geral 4, ou um isômero, uma forma cristalina, um sal farmaceuticamente aceitável, um hidrato ou um solvato do mesmo; composto de fórmula geral 5, ou um isômero, uma forma cristalina, um sal farmaceuticamente aceitável, um hidrato ou um solvato do mesmo; composição farmacêutica; e; uso do composto, ou do isômero, da forma cristalina, do sal farmaceuticamente aceitável, do hidrato ou do solvato do mesmo
TW202304911A (zh) * 2021-04-23 2023-02-01 大陸商南京明德新藥研發有限公司 吡啶醯胺類化合物
WO2022222966A1 (zh) * 2021-04-23 2022-10-27 成都百裕制药股份有限公司 一种选择性parp1抑制剂及其应用
CA3219248A1 (en) 2021-05-18 2022-11-24 Hyun Ju Cha Parp inhibitor-resistant cancer therapeutic agent
CA3219303A1 (en) 2021-05-18 2022-11-24 Onconic Therapeutics Inc. Crystalline form of tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same
WO2023011608A1 (zh) * 2021-08-05 2023-02-09 上海枢境生物科技有限公司 含三并环类衍生物调节剂、其制备方法和应用
WO2023025307A1 (en) * 2021-08-27 2023-03-02 Impact Therapeutics (Shanghai) , Inc Substituted tricyclic compounds as parp inhibitors and use thereof
WO2023036285A1 (zh) * 2021-09-09 2023-03-16 南京奥利墨斯医药科技有限公司 一种杂芳环类化合物及其应用
WO2023046034A1 (zh) * 2021-09-22 2023-03-30 明慧医药（杭州）有限公司 一种含氮杂环化合物、其制备方法、其中间体及其应用
US20230159525A1 (en) 2021-10-01 2023-05-25 Xinthera, Inc. Azetidine and pyrrolidine parp1 inhibitors and uses thereof
WO2023061406A1 (zh) * 2021-10-12 2023-04-20 微境生物医药科技(上海)有限公司 含三并环结构的parp抑制剂、及其制备方法和医药用途
TW202332438A (zh) * 2021-12-22 2023-08-16 美商思諾維新醫藥公司 Ｐａｒｐ１抑制劑
CN116425744A (zh) * 2022-01-13 2023-07-14 优领医药科技(香港)有限公司 含哌嗪并环类衍生物、其药学上可接受的盐及其制备方法和应用
US11939329B2 (en) 2022-01-21 2024-03-26 Xinthera, Inc. PARP1 inhibitors and uses thereof
WO2023169226A1 (en) * 2022-03-11 2023-09-14 Impact Therapeutics (Shanghai), Inc Substituted tricyclic compounds as parp inhibitors and the use thereof
TW202400596A (zh) 2022-04-28 2024-01-01 美商辛瑟拉股份有限公司 三環parp1抑制劑及其用途
WO2023217045A1 (zh) * 2022-05-07 2023-11-16 南京明德新药研发有限公司 选择性抑制parp1的氟代喹喔啉酮衍生物
CN115232129B (zh) * 2022-08-18 2023-12-01 上海闻耐医药科技有限公司 一种parp1选择性抑制剂及其制备方法和用途
WO2024041605A1 (zh) * 2022-08-24 2024-02-29 四川海思科制药有限公司 一种杂芳基衍生物parp抑制剂药学上可接受的盐及其用途
WO2024041608A1 (zh) * 2022-08-24 2024-02-29 四川海思科制药有限公司 一种杂芳基衍生物parp抑制剂的晶体形式及其用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5391554A (en) 1992-09-09 1995-02-21 Warner-Lambert Company Dihydro- and tetrahydronaphthyridines
AUPS137402A0 (en) 2002-03-26 2002-05-09 Fujisawa Pharmaceutical Co., Ltd. Novel tricyclic compounds
DE102004028973A1 (de) 2004-06-16 2006-01-05 Sanofi-Aventis Deutschland Gmbh Substituierte Tetrahydro-2H-isochinolin-1-on-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
DK2061765T3 (en) * 2006-09-01 2015-01-26 Senhwa Biosciences Inc Serine-threonine protein kinase AND PARP-MODULATOR
PL2215075T3 (pl) 2007-10-26 2014-04-30 Janssen Pharmaceutica Nv Pochodne chinolinonu jako inhibitory PARP
KR101179753B1 (ko) 2007-11-06 2012-09-04 제일약품주식회사 신규한 트리시클릭 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 포함하는 약학조성물
WO2010056038A2 (ko) * 2008-11-11 2010-05-20 제일약품주식회사 신규한 트리시클릭 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 포함하는 약학적 조성물
KR101827444B1 (ko) 2012-02-01 2018-02-08 제일약품주식회사 트리사이클로 유도체 화합물의 신규한 결정형 산부가염 또는 이의 수화물 및 이의 제조방법
NZ738187A (en) * 2015-06-09 2019-03-29 Je Il Pharmaceutical Co Ltd Tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same
KR101775356B1 (ko) * 2015-07-06 2017-09-06 재단법인 아산사회복지재단 Parp 및 탄키라제 동시 저해제에 대한 감수성 결정 방법

Also Published As

Publication number Publication date
KR20160144916A (ko) 2016-12-19
EP3312177B1 (en) 2021-04-14
PH12017502228A1 (en) 2018-06-11
CN107849040A (zh) 2018-03-27
ES2870203T3 (es) 2021-10-26
PL3312177T3 (pl) 2021-11-02
BR112017026392B1 (pt) 2023-12-26
BR112017026392A2 (es) 2018-08-21
JP6806969B2 (ja) 2021-01-06
RU2017146130A (ru) 2019-07-16
AU2016276806A1 (en) 2018-01-04
AU2016276806B2 (en) 2019-02-14
CA2990277C (en) 2021-10-26
PT3312177T (pt) 2021-05-17
EP3312177A4 (en) 2018-12-05
RU2715413C2 (ru) 2020-02-28
DK3312177T3 (da) 2021-07-05
NZ738187A (en) 2019-03-29
US10464919B2 (en) 2019-11-05
JP2019163287A (ja) 2019-09-26
JP2018521033A (ja) 2018-08-02
ZA201708663B (en) 2019-04-24
CN107849040B (zh) 2021-04-06
CA2990277A1 (en) 2016-12-15
US20180162834A1 (en) 2018-06-14
CL2017003138A1 (es) 2018-06-15
AU2016276806B9 (en) 2019-02-21
WO2016200101A3 (ko) 2017-02-02
KR101837047B1 (ko) 2018-03-09
EP3312177A2 (en) 2018-04-25
RU2017146130A3 (es) 2019-07-17
SA517390509B1 (ar) 2021-06-02
MY194590A (en) 2022-12-05
WO2016200101A2 (ko) 2016-12-15

Similar Documents

Publication Publication Date Title
PH12017502228A1 (en) Tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same
PH12017501921A1 (en) Novel compounds
PH12018502507A1 (en) Pyrazolopyrimidine derivatives as kinase inhibitor
NZ742742A (en) Compositions and methods for inhibiting arginase activity
WO2016130920A3 (en) Lrrk2 inhibitors and methods of making and using the same
TW201613901A (en) New compounds
EP3995581A3 (en) Oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders
WO2015200481A8 (en) Mnk inhibitors and methods related thereto
NZ728162A (en) Heteroaryl compounds useful as inhibitors of sumo activating enzyme
PH12016501702B1 (en) Pyrazole amide derivative
MX2017011778A (es) Compuestos y composiciones de alfa-cinamida como inhibidores de histona desacetilasa 8 (hdac8).
PH12019502363A1 (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
MX2020006237A (es) Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4.
IL261196B (en) Pharmaceutical composition for treatment of cancer, containing polyphenol compound as active ingredient
AU2016380190A8 (en) Deuterated compounds for treating cancer and related diseases and conditions, and compositions and methods thereof
MX2019006863A (es) Inhibidores de heparanasa y uso de los mismos.
MX2019001634A (es) Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos.
WO2015077535A3 (en) Novel methods for treating neurodegenerative diseases
MY194015A (en) Sodium channel blocker
MX2018002177A (es) Nuevo derivado de catecol y composicion farmaceutica que comprende el mismo.
WO2016020408A3 (en) Compounds for preventing ototoxicity
PH12020500233A1 (en) Adamantylmethylamine derivative and use thereof as pharmaceutical
AU2019268209A1 (en) Compounds for the treatment of seizures and other central nervous system disorders and conditions
MX2018006631A (es) Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas.
EA201991971A1 (ru) Применение фенилкреатина для профилактики или лечения экстрасистолии

Legal Events

Date Code Title Description
FG Grant or registration
PD Change of proprietorship

Owner name: ONCONIC THERAPEUTICS INC.